NZ219192A - Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines - Google Patents

Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines

Info

Publication number
NZ219192A
NZ219192A NZ219192A NZ21919287A NZ219192A NZ 219192 A NZ219192 A NZ 219192A NZ 219192 A NZ219192 A NZ 219192A NZ 21919287 A NZ21919287 A NZ 21919287A NZ 219192 A NZ219192 A NZ 219192A
Authority
NZ
New Zealand
Prior art keywords
vaccines
melanoma
recombinant virus
associated peptide
peptides related
Prior art date
Application number
NZ219192A
Other languages
English (en)
Inventor
Joseph P Brown
Gregory D Plowman
Karl E Hellstrom
Anthony F Purchio
Sridhar Pennathur
Charles D Estin
Timothy M Rose
Shiu-Lok Hu
Ingegerd Hellstrom
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26676698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ219192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/007,230 external-priority patent/US5262177A/en
Application filed by Oncogen filed Critical Oncogen
Priority to NZ23226787A priority Critical patent/NZ232267A/xx
Publication of NZ219192A publication Critical patent/NZ219192A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ219192A 1986-02-07 1987-02-05 Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines NZ219192A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ23226787A NZ232267A (en) 1986-02-07 1987-02-05 Vectors, microorganisms and cell lines relating to p97b melanoma protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82731386A 1986-02-07 1986-02-07
US07/007,230 US5262177A (en) 1986-02-07 1987-01-27 Recombinant viruses encoding the human melanoma-associated antigen

Publications (1)

Publication Number Publication Date
NZ219192A true NZ219192A (en) 1991-10-25

Family

ID=26676698

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ219192A NZ219192A (en) 1986-02-07 1987-02-05 Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines

Country Status (18)

Country Link
JP (3) JP2664673B2 (sv)
BE (1) BE1000175A3 (sv)
CH (1) CH675424A5 (sv)
DE (1) DE3703702C2 (sv)
DK (1) DK63287A (sv)
ES (2) ES2012815A6 (sv)
FI (1) FI94836C (sv)
GR (1) GR870195B (sv)
HU (1) HU209144B (sv)
IE (1) IE59597B1 (sv)
IT (1) IT1222359B (sv)
MX (1) MX9203574A (sv)
NL (1) NL8700285A (sv)
NO (1) NO178931C (sv)
NZ (1) NZ219192A (sv)
OA (1) OA08478A (sv)
PT (1) PT84255B (sv)
SE (2) SE506024C2 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821925A1 (de) * 1998-05-15 1999-11-18 Roehnisch Tim Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Also Published As

Publication number Publication date
IE59597B1 (en) 1994-03-09
FI94836C (sv) 1995-11-10
HU209144B (en) 1994-03-28
FI870501A0 (sv) 1987-02-06
DK63287D0 (da) 1987-02-06
IT1222359B (it) 1990-09-05
FI870501A (sv) 1987-08-08
PT84255A (en) 1987-03-01
ES2012815A6 (es) 1990-04-16
OA08478A (fr) 1988-07-29
DK63287A (da) 1987-08-08
SE9202934D0 (sv) 1992-10-07
HUT43107A (en) 1987-09-28
NO870475D0 (no) 1987-02-06
SE8700466L (sv) 1987-08-08
NL8700285A (nl) 1987-09-01
JPH09135692A (ja) 1997-05-27
IT8719291A0 (it) 1987-02-06
SE8700466D0 (sv) 1987-02-06
PT84255B (pt) 1989-11-30
SE506024C2 (sv) 1997-11-03
JPS62294698A (ja) 1987-12-22
JPH08280390A (ja) 1996-10-29
NO870475L (no) 1987-08-10
JP2664673B2 (ja) 1997-10-15
ES2017258A6 (es) 1991-01-16
FI94836B (sv) 1995-07-31
GR870195B (en) 1987-06-10
BE1000175A3 (fr) 1988-07-12
IE870319L (en) 1987-08-07
DE3703702C2 (de) 1997-07-10
CH675424A5 (en) 1990-09-28
NO178931C (no) 1996-07-03
DE3703702A1 (de) 1988-02-18
MX9203574A (es) 1992-07-01
NO178931B (no) 1996-03-25

Similar Documents

Publication Publication Date Title
EP0273716A3 (en) Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
AR241940A1 (es) Metodo para construir un vector de expresion recombinante de virus de polihedrosis nuclear de autographa californica, sintesis y purificiacion.
ZA896715B (en) Fusion protein of paramyxovirus,method of production using recombinant baculovirus expression vector,vaccine comprising such protein and use thereof
GB2246784A (en) Herpes virus recombinant poxvirus vaccine
IL90489A0 (en) Recombinant coccidiosis vaccines and their preparation
NZ211880A (en) Immunogenic, leukemia-associated viral proteins and vaccines
IL81839A0 (en) Polypeptide,dna and its use
NZ224046A (en) Hiv antigenic peptide fragments and their use
EP0467700A3 (en) Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
GB2218421B (en) A process for producing envelope protein of japanese encephalitis virus using recombinant baculovirus; envelope proteins,recombinant baculovirus and vaccines
GB8821528D0 (en) Recombinant vaccinia virus
EP0491844A4 (en) Peptides including ctl epitopes of hiv proteins and use thereof
GB2203740B (en) Novel peptides, their preparation and use
NZ229679A (en) Recombinant dna sequence encoding an emeria peptide, the peptide and poultry vaccine against coccidiosis
EP0525828A3 (en) Recombinant polypeptides and their uses, including assay for aids virus
HUT44622A (en) New antigen-active proteins and peptides and feline peritonitis virus vaccine (fipv)
ZA875819B (en) Homogeneous recombinant immune interferon fragments
NZ219192A (en) Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines
DK575787A (da) Rekombinant hcmv-afledt plasmid, dets fremstilling og anvendelse
NZ224393A (en) Recombinant hiv envelope proteins and uses thereof
ZA852629B (en) A peptide vaccine or diagnostic,and a polypeptide useful therefor
NZ217400A (en) Recombinant virus optimised to increase immunogenicity of expressed foreign peptides; dna molecule and peptide
HUT43110A (en) New antigene-active proteines and peptides and infective bronchitis virus /ibv/ vaccines
PT86162A (en) Recombinant protein expression